Latest Conference Articles

The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and chemotherapy alone.

Shirish M. Gadgeel, MD, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology Congress.

The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.

Data from the phase 2 PECATI trial support the use of lenvatinib plus pembrolizumab as a potential standard treatment for patients with advanced B3-thymoma and thymic carcinoma.

The BR.31 trial found that adjuvant durvalumab did not improve disease-free survival in patients with non-small cell lung cancer, regardless of PD-L1 expression.

Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.

The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.

In this preview, we highlight the key late-breaking abstracts to be presented at the 2024 ESMO Congress across various tumor types that may impact clinical practice.

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

Firmonertinib showed efficacy and safety in patients with EGFR PACC-mutated non–small cell lung cancer.

Golcadomide plus R-CHOP was well tolerated and demonstrated high metabolic response rates that were durable in patients with previously untreated a-BCL.

Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.

Michael J. Mauro, MD, provides a summary of a presentation at the 2024 Society of Hematologic Oncology Annual Meeting on the recent advancements in CML treatment and applying clinical evidence to cases that are advanced.

Response outcomes with liso-cel were consistent regardless of the presence of high-risk disease features in patients with relapsed/refractory chronic lymphocytic leukemia.

While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.

Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.

Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.

Imetelstat sustained red blood cell transfusion independence in patients with lower-risk myelodysplastic syndrome, with most responders experiencing durable responses.

Partow Kebriaei, MD, discusses transplant in acute lymphoblastic leukemia.

Sonali M. Smith, MD, discusses how T-cell–directed therapies work in the context of indolent B-cell lymphoma.

The use of CAR T-cell therapy tisagenlecleucel has decreased the need for HSCT in pediatric and young adult patients with relapsed/refractory B-ALL, according to data from a noninterventional study.

Reid W. Merryman, MD, discussed the latest developments with minimal residual disease assays in the management of patients with lymphoma.

Harnessing the power of the immune system has emerged as a key approach in addressing T-cell malignancies, with efforts to leverage the immune system leading to significant improvements beyond the traditional scope of surgery, radiation therapy, and chemotherapy.

Sergio A. Giralt, MD, discusses the current indications for considering stem cell transplants in patients with myelodysplastic syndrome.

Stefan Barta, MD, discusses the heterogeneity of T-cell lymphoma, highlighting that a one-size-fits-all approach is ineffective and emphasizing the need for tailored treatment approaches.

Juneko Grilley-Olson, MD, discussed findings from a phase 2 study investigating the addition of immunotherapy to chemotherapy for the treatment of advanced angiosarcoma.

Barbara O'Brien, MD, discusses the goals and results of a study investigating tucatinib, trastuzumab, and capecitabine for the treatment of leptomeningeal metastases in patients with HER2-positive breast cancer.